{
    "clinical_study": {
        "@rank": "83953", 
        "arm_group": {
            "arm_group_label": "Group A", 
            "arm_group_type": "Experimental", 
            "description": "Exenatide injection 5mcg or 10 mcg, twice daily"
        }, 
        "brief_summary": {
            "textblock": "The aim of this study is to assess the long-term safety of exenatide in patients with type 2\n      diabetes who were treated with exenatide in Study H8O-MC-GWAA (6-month study) or Study\n      H8O-MC-GWAD (12-month study).  Study H8O-MC-GWAN serves as an open-ended extension to\n      Studies H8O-MC-GWAA and H8O-MC-GWAD."
        }, 
        "brief_title": "An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "July 2008", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients received exenatide therapy in Study H8O-MC-GWAA or Study H8O-MC-GWAD and\n             completed the respective study.\n\n        Exclusion Criteria:\n\n          -  Patients were excluded or discontinued early from Study H8O-MC-GWAA or Study\n             H8O-MC-GWAD.\n\n          -  Patients have received treatment within the last 30 days with a drug, not including\n             exenatide, that has not received regulatory approval for any indication at the time\n             of study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "275", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 14, 2009", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01876849", 
            "org_study_id": "H8O-MC-GWAN"
        }, 
        "intervention": {
            "arm_group_label": "Group A", 
            "description": "subcutaneous injection, 5mcg or 10 mcg, twice daily", 
            "intervention_name": "exenatide", 
            "intervention_type": "Drug", 
            "other_name": "Byetta"
        }, 
        "intervention_browse": {
            "mesh_term": "Exenatide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "diabetes", 
            "exenatide", 
            "Byetta", 
            "Amylin", 
            "Lilly"
        ], 
        "lastchanged_date": "October 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Renton", 
                    "country": "United States", 
                    "state": "Washington"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Chief Medical Officer, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Visits for this study occur at 6-mo (\u00b12 wk) intervals until exenatide is approved for marketing.", 
            "measure": "Long-term safety of twice-daily exenatide treatment, as defined by the occurrence of adverse events.", 
            "safety_issue": "No", 
            "time_frame": "128 weeks (average treatment period)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01876849"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "collaborator": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2003", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}